Nathan John Lachowsky – The Conversation

The HIV prevention drug cabotegravir, which is delivery by injection every eight weeks, is not yet available in Canada. (Shutterstock)

December 18, 2022

Long‑acting injectable PrEP is a big step forward in HIV prevention

Michael Montess, Western University; Darrell Tan, University of Toronto, and Nathan John Lachowsky, University of Victoria

The next step in HIV prevention — long-acting injectable pre-exposure prophylaxis (PrEP) — is not yet available in Canada, a year after its approval in the U.S.

Thousands gather in downtown Toronto in 2006 for a candlelight vigil to remember those who have died from AIDS. (CP PHOTO/Nathan Denette)

May 13, 2021

HIV survivors’ stories show the loss, resilience and activism of the early years of AIDS pandemic

Michael Montess, University of Victoria and Nathan John Lachowsky, University of Victoria

The HIV In My Day project preserves the early history of the HIV/AIDS pandemic through the personal stories of long-term survivors and caregivers.

People living with HIV/AIDS all over the world are still struggling with stigma due to perceptions of the virus as dark and shameful. Here a Filipino man lights candles at a World AIDS Day even in Quezon city, Philippines in 2016. (AP Photo/Aaron Favila)

November 29, 2018

What you need to know about HIV/AIDS today

Nathan John Lachowsky, University of Victoria; Gbolahan Olarewaju, University of British Columbia, and Heather Armstrong, University of British Columbia

Researchers from the BC Centre for Excellence in HIV/AIDS share the latest research on HIV prevention, treatment and stigma.

Contact Nathan for